Related Experiment Videos
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee1, Seong-Eun Kim2, Yong Eun Park3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.
Insights
COVID-19 vaccination is strongly recommended for inflammatory bowel disease (IBD) patients. Evidence indicates that severe acute respiratory syndrome coronavirus 2 vaccines are safe for IBD patients, even those on immunomodulatory therapy.
Area of Science:
- Immunology
- Gastroenterology
- Vaccinology
Background:
- The COVID-19 pandemic poses a significant global health threat.
- Vaccination is the primary strategy for controlling COVID-19.
- Limited data exists on COVID-19 vaccine safety and efficacy in inflammatory bowel disease (IBD) patients.
Purpose of the Study:
- To provide an expert consensus on COVID-19 vaccination for Korean IBD patients.
- To address concerns regarding the safety and efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in IBD patients.
Main Methods:
- Review of current evidence and international guidelines.
- Development of an expert consensus statement by the Korean Association for the Study of Intestinal Diseases.
Main Results:
- COVID-19 vaccination is strongly recommended for all IBD patients.
- SARS-CoV-2 vaccination is considered safe for IBD patients undergoing immunomodulatory therapy.
Conclusions:
- IBD patients should be prioritized for COVID-19 vaccination.
- Immunomodulatory therapy does not contraindicate SARS-CoV-2 vaccination in IBD patients.